Cibc World Market Inc. Acquires Shares of 234,673 Eupraxia Pharmaceuticals Inc. $EPRX

Key Points

• CIBC World Market Inc. acquired 234,673 shares of Eupraxia Pharmaceuticals in the second quarter, worth approximately $1.54 million and representing a 0.36% stake.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $18.00, compared with the stock’s reported price of $7.36.
• Eupraxia reported a quarterly loss of $0.23 per share, beating estimates by $0.02. The clinical-stage biotechnology company is developing therapies for autoimmune and inflammatory diseases, with its lead candidate in Phase 1 trials for systemic lupus erythematosus.

Cibc World Market Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 234,673 shares of the company's stock, valued at approximately $1,539,000. Cibc World Market Inc. owned 0.36% of Eupraxia Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in EPRX. Persistent Asset Partners Ltd purchased a new position in shares of Eupraxia Pharmaceuticals in the second quarter worth $25,000. BlackRock Inc. purchased a new stake in Eupraxia Pharmaceuticals during the 2nd quarter valued at $40,000. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at $71,000. Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock worth $72,000 after acquiring an additional 10,059 shares during the last quarter. Finally, Aptus Capital Advisors LLC bought a new stake in Eupraxia Pharmaceuticals in the 4th quarter worth $76,000.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EPRX. Cantor Fitzgerald restated an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Thursday, May 7th. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, May 16th. Finally, Oppenheimer began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an "outperform" rating and a $17.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Eupraxia Pharmaceuticals Stock Down 0.9%

NASDAQ:EPRX opened at $7.36 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The firm's 50-day moving average price is $6.60 and its 200-day moving average price is $7.04. The company has a market capitalization of $478.55 million, a PE ratio of -7.22 and a beta of 1.08. Eupraxia Pharmaceuticals Inc. has a 1-year low of $5.12 and a 1-year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. On average, equities analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.87 EPS for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source